Albus Health Expands Leadership Team to Support Global Growth in Contactless Nocturnal Monitoring

OXFORD, England, Sept. 24, 2026 /PRNewswire/ -- Albus Health, a leader in multimodal nocturnal health monitoring, has expanded its senior leadership team with two key appointments as the company accelerates international deployment of its contactless, clinical‑grade monitoring platform for multinational clinical trials.

Jonathan Day has been named Head of Quality Assurance and Regulatory Affairs, and Dr Samantha Macro joins as fractional Chief Financial Officer. The appointments strengthen Albus Health's capability to deliver regulator‑ready, real‑world nocturnal health data at scale, supporting clinical trial programs from early research through to commercial execution.

Albus Health's flagship bedside system, Albus Home, uses advanced sensors and AI algorithms to capture continuous nocturnal data including cough, vital signs, sleep parameters, and environmental factors. The platform is operational in more than 50 countries supporting pharmaceutical companies, academic institutions, and patient advocacy groups conducting clinical research and long‑term disease monitoring.

"With market adoption growing rapidly, we are strengthening the structures that support scale and enable our users to gain more value from Albus," said Mikesh Udani, Co-founder & CEO, Albus Health. "Samantha and Jonathan bring extensive experience in the pharma and healthcare markets, particularly with companies in the growth phase."

Jonathan Day brings more than 25 years of experience across medical devices and Software as a Medical Device (SaMD), with a career spanning the US, UK, and Switzerland. His background includes regulatory strategy and submissions, quality and compliance program development, remediation and transformation initiatives, process excellence, and new product introduction.

Samantha Macro has more than 20 years of finance leadership experience in biotech and established pharmaceutical companies. She has served as a fractional and full‑time CFO for organizations including AstraZeneca, MedImmune, Cambridge Antibody Technology, and Mestag Therapeutics. Her experience includes supporting teams to secure $45 million in seed financing and contributing to strategic and M&A initiatives during preparations for a NASDAQ listing.

Both join an established management team and Board of Directors comprising clinicians, respiratory and sleep researchers, and medtech industry leaders. The Board includes Co‑founders Mikesh Udani and Dr William Do, and Non‑Executive Director Colin Reisner, the former CEO of Pearl Therapeutics (acquired by AstraZeneca) and a physician with over 25 years' experience including leadership roles at AstraZeneca, GSK, Novartis and Boehringer Ingelheim.

About Albus Health Albus Health develops contactless nocturnal monitoring systems that support clinical trials, real‑world evidence programs, and chronic disease management. Learn more at www.albushealth.com.

For more information, contact: [email protected]

SOURCE Albus Health